Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
On a field-in-field breast tangent plan do you have a minimum MU you accept for a subfield?
Answer from: Radiation Oncologist at Community Practice
I usually avoid sub field with MU, less than 4-5 as adds little to plan quality and increases treatment time.
Sign in or Register to read more
15098
Related Questions
How do you weigh upfront nodal burden when deciding to omit PMRT in a patient with cN1, ypN0 disease after neoadjuvant chemo, mastectomy and ALND?
When should the dissected axilla (levels I-II) be included when delivering RNI?
Is there any contraindication for a patient receiving omalizumab for treatment of her lung aspergillosis to receive adjuvant breast radiotherapy?
How do you optimally set a patient up for breast radiation therapy if you don't have access to a breast board or wing board?
Should PMRT be offered for ypN0(i+) disease if only 1-2 nodes were removed in the post-chemotherapy SLNB and there is no plan for a completion AxLND?
Is FAST-Forward/ultra-hypofractionation suitable for an early-stage breast patient after a lumpectomy with oncoplastic reduction?
Do you hold endocrine therapy during adjuvant breast radiotherapy?
In a clinically node negative early stage breast cancer patient who underwent neoadjuvant systemic therapy, would surgical finding of fibrosis suspicious for treatment effect in sentinel nodes impact your RT decision?
Would you recommend PMRT for multifocal IDC with extensive LVI and 1 SLN with ITCs?
What is the appropriate approach to manage a patient with triple-negative, locally advanced breast cancer (LN+) who progresses on neoadjuvant chemo-immunotherapy (KEYNOTE-522 regimen)?